Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 4, 2014, Pages 729-736

  Rudek, Michelle A ^a   Chang, Cathy Y ^a   Steadman, Kenneth ^b   Johnson, Michael D ^b   Desai, Naveen ^b   Deeken, John F ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antiretrovirals; Docetaxel; Drug interaction; HIV; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A11; CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; EFAVIRENZ; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG LIVER LEVEL; GENE EXPRESSION; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZINES; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; HIV PROTEASE INHIBITORS; KETOCONAZOLE; LIVER; MALE; MICE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TAXOIDS;

EID: 84898057904     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2399-7     Document Type: Article

References (48)

1. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753-762. doi: 10.1093/jnci/djr076
2. Deeken JF, Tjen ALA, Rudek MA, Okuliar C, Young M, Little RF, Dezube BJ (2012) The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 55(9):1228-1235. doi: 10.1093/cid/cis613
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338(13):853-860. doi: 10.1056/NEJM199803263381301
4. Services DoHaH (Last updated February 12, 2013) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 30 March 2013
5. Rudek MA, Flexner C, Ambinder RF (2011) Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 12(9):905-912. doi: 10.1016/S1470-2045(11)70056-0
6. Minuesa G, Huber-Ruano I, Pastor-Anglada M, Koepsell H, Clotet B, Martinez-Picado J (2011) Drug uptake transporters in antiretroviral therapy. Pharmacol Ther 132(3):268-279. doi: 10.1016/j.pharmthera.2011.06.007
7. Kis O, Robillard K, Chan GN, Bendayan R (2010) The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31(1):22-35. doi: 10.1016/j.tips.2009.10.001
8. Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277(1):423-431
9. Kharasch ED, Mitchell D, Coles R, Blanco R (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 52(5):1663-1669. doi: 10.1128/AAC.01600-07
10. Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A, Kashuba AD (2004) Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 36(5):1034-1040
11. Kageyama M, Namiki H, Fukushima H, Terasaka S, Togawa T, Tanaka A, Ito Y, Shibata N, Takada K (2005) Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull 28(1):130-137
12. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J (2007) Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73(10):1573-1581. doi: 10.1016/j.bcp.2007.01.027
13. Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44(2):190-194
14. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW (2003) A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 36(12):1585-1592
15. von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, Harmatz JS, Shader RI (2001) Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 41(1):85-91
16. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA (2005) Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 39(3):307-312
17. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB (2004) Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44(11):1273-1281
18. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72(1):1-9. doi: 10.1067/mcp.2002. 124519
19. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320(1):72-80. doi: 10.1124/jpet.106.112136
20. Burhenne J, Matthee AK, Pasakova I, Roder C, Heinrich T, Haefeli WE, Mikus G, Weiss J (2010) No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother 54(10):4185-4191. doi: 10.1128/AAC.00283-10
21. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991-4997. doi: 10.1200/JCO.2006.06.8429
22. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, del Viroglio RC, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705-1715. doi: 10.1056/NEJMoa070956
23. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695-1704. doi: 10.1056/NEJMoa071028
24. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21(16):3016-3024. doi: 10.1200/JCO.2003.12.046
25. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354-2362
26. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21(6):968-975
27. Sanofi-Aventis (2010) Taxotere Package Insert: Prescribing Information
28. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502-1512. doi: 10.1056/NEJMoa040720
29. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56(6):1296-1302
30. Baker SD, Sparreboom A, Verweij J (2006) Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45(3):235-252
31. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48(7):1528-1530
32. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37(11):3594-3601. doi: 10.1021/bi972709x
33. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75(5):448-454. doi: 10.1016/j.clpt.2004.01.001
34. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187-196
35. Rudek MA, Ambinder RF, Flexner CW, Deeken JF (2012) Systemic therapy for malignancy in patients on anti retroviral medications. UpToDate, Waltham, MA
36. Corcos L (1992) Phenobarbital and dexamethasone induce expression of cytochrome P-450 genes from subfamilies IIB, IIC, and IIIA in mouse liver. Drug Metab Dispos Biol Fate Chem 20(6):797-801
37. Manceau S, Giraud C, Decleves X, Batteux F, Chereau C, Chouzenoux S, Scherrmann JM, Weill B, Perrot JY, Treluyer JM (2012) Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line. J Chemother 24(1):48-55. doi: 10.1179/1120009X12Z. 00000000010
38. Tampellini M, Filipski E, Liu XH, Lemaigre G, Li XM, Vrignaud P, Francois E, Bissery MC, Levi F (1998) Docetaxel chronopharmacology in mice. Cancer Res 58(17):3896-3904
39. Rudek MA, Zhao M, Smith NF, Robey RW, He P, Hallur G, Khan S, Hidalgo M, Jimeno A, Colevas AD, Messersmith WA, Wolff AC, Baker SD (2005) In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clin Cancer Res 11(23):8503-8511. doi: 10.1158/1078-0432.CCR-05-1037
40. von Moltke LL, Granda BW, Grassi JM, Perloff MD, Vishnuvardhan D, Greenblatt DJ (2004) Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab Dispos 32(8):800-804
41. Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A (2004) Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem 324(2):276-284
42. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16(3):303-309
43. Yuan J (1993) Estimation of variance for AUC in animal studies. J Pharm Sci 82(7):761-763
44. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62(21):6158-6164
45. Loulergue P, Mir O, Allali J, Viard JP (2008) Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma. Aids 22(10):1237-1239. doi: 10.1097/QAD.0b013e328300ca98
46. Mir O, Dessard-Diana B, Louet AL, Loulergue P, Viard JP, Langlois A, Durdux C, Le Beller C (2010) Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. Br J Clin Pharmacol 69(1):99-101. doi: 10.1111/j.1365-2125.2009.03555.x
47. Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH (2009) Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res 15(12):4228-4233. doi: 10.1158/1078-0432.CCR-08-2944
48. Yong WP, Wang LZ, Tham LS, Wong CI, Lee SC, Soo R, Sukri N, Lee HS, Goh BC (2008) A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer Chemother Pharmacol 62(2):243-251. doi: 10.1007/s00280-007-0598-1